Updates are available Correction dated 2021-07-19
Click to view Correction: https://doi.org/10.1038/s41467-021-24770-w
-
Authors
Zhang, Liyang
Zuris, John A.
Viswanathan, Ramya
Edelstein, Jasmine N.
Turk, Rolf https://orcid.org/0000-0003-1283-9594
Thommandru, Bernice
Rube, H. Tomas
Glenn, Steve E.
Collingwood, Michael A.
Bode, Nicole M. https://orcid.org/0000-0001-7209-303X
Beaudoin, Sarah F. https://orcid.org/0000-0001-9337-3022
Lele, Swarali
Scott, Sean N.
Wasko, Kevin M.
Sexton, Steven
Borges, Christopher M.
Schubert, Mollie S.
Kurgan, Gavin L. https://orcid.org/0000-0002-4047-1427
McNeill, Matthew S. https://orcid.org/0000-0002-8737-785X
Fernandez, Cecilia A.
Myer, Vic E.
Morgan, Richard A.
Behlke, Mark A. https://orcid.org/0000-0002-4218-857X
Vakulskas, Christopher A. https://orcid.org/0000-0001-8510-4332
- License Information
-
More Information
Article History
Received: 4 September 2020
Accepted: 1 June 2021
First Online: 23 June 2021
Change Date: 19 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-24770-w
Competing interests
: H.T.R. declares no competing financial interests. L.Z., R.T., B.T., S.E.G., M.A.C., N.M.B., S.F.B., M.S.S., G.L.K., M.S.M., M.A.B., and C.A.V. are employees of Integrated DNA technologies, (IDT), which sells reagents described in this manuscript. C.A.V. and M.A.B. own equity in the Danaher Corporation, which is the parent company of Integrated DNA Technologies. J.A.Z., R.V., S.L., S.N.S., K.M.W., and S.S. are current employees and shareholders of Editas Medicine. J.N.E., C.M.B., C.A.F., V.E.M., and R.A.M. are previous employees and shareholders of Editas Medicine and were employed by Editas at the time this work was conducted. Editas Medicine uses the reagents described in this manuscript to generate cell medicines. IDT and Editas Medicine have filed patents pertaining to the work described in this manuscript. Integrated DNA Technologies has a pending patent application (US20200109382A1) for the AsCas12a mutants described in this manuscript (C.A.V., L.Z., N.M.B., M.A.C., and M.A.B.). Editas Medicine has a patent pending (WO2019178426A1) for some of the clinical genome editing methods described in this manuscript (J.A.Z.).
